AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34173669
Drug: PIs having
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PIs having accepted payment(s) from the manufacturer of the drug utilized in their RCT
Trial: 32101663
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus neoadjuvant chemotherapy (200 mg every 3 weeks)
Trial: 32101663
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus neoadjuvant chemotherapy
Trial: 34470186
Drug: MNT administered
RxNorm normalized name: MNTX
DrugBank: Methylnaltrexone (DB06800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: MNT administered monthly (Group A)
Trial: 34470186
Drug: MNT administered
RxNorm normalized name: MNTX
DrugBank: Methylnaltrexone (DB06800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: MNT administered every 3 months (Group B)
Trial: 34470186
Drug: No access
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No access to nutritional therapy (Group C)
Trial: 36282220
Drug: Erector spinae
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erector spinae plane block (ESPB) with 20 mL 0.375% bupivacaine
Trial: 36282220
Drug: Thoracal paravertebral
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracal paravertebral block (TPVB) with 20 mL 0.375% bupivacaine
Trial: 35957925
Drug: Serum glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum glucose > 120 mg/dL
Trial: 35957925
Drug: Serum cortisol
RxNorm normalized name: Serum cortisol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum cortisol > 10 μg/dL
Trial: 35957925
Drug: Leptin ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptin ≥ 15 ng/mL
Trial: 35957925
Drug: GDNF ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDNF ≥ 20 pg/mL
Trial: 33840474
Drug: Oxygen delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen delivery strategy (maintaining an oxygen delivery index value >300 mL/min/m2 through pump flow adjustments)
Trial: 32861603
Drug: Taurine 3,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurine 3,000 mg/day for 8 weeks
Trial: 34748214
Drug: Conversational agent
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conversational agent (dialogic reading)
Trial: 34563585
Drug: Luseogliflozin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luseogliflozin 2.5 mg/day
Trial: 35102226
Drug: Desogestrel (DSG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desogestrel (DSG 150 µg/d, n=50)
Trial: 35102226
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA 10 mg/d, n=54)
Trial: 32346706
Drug: Continuous curvilinear
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous curvilinear buccal‐cervical incision
Trial: 32346706
Drug: Conventional cervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cervical T shaped incision combined with a buccal incision
Trial: 34528981
Drug: LGG fermented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LGG fermented milk (150 mL containing 108 CFU mL‐1 LGG)
Trial: 35822565
Drug: medication withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medication withdrawal
Trial: 35881121
Drug: High-dose tranexamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tranexamic acid (30 mg/kg bolus, 16 mg/kg/h maintenance, 2 mg/kg prime)
Trial: 35881121
Drug: Low-dose tranexamic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tranexamic acid (10 mg/kg bolus, 2 mg/kg/h maintenance, 1 mg/kg prime)
Trial: 35881121
Drug: High-dose tranexamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tranexamic acid
Trial: 32279172
Drug: Antiviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral therapy (AVT)
Trial: 35610712
Drug: CHW-led intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CHW-led intervention (monthly household visits for 1 year)
Trial: 34051389
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of HPV vaccine
Trial: 34051389
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of HPV vaccine
Trial: 34159751
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of amlodipine 5 mg, losartan 100 mg, and chlorthalidone 25 mg
Trial: 34159751
Drug: Separate components
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate components (loose combination) of amlodipine/losartan 5/100 mg and chlorthalidone 25 mg
Trial: 38844004
Drug: Fluticasone furoate/umeclidinium/vilanterol
RxNorm normalized name: Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy
Trial: 33910578
Drug: Fibrinogen levels
RxNorm normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen levels ≥ 3.5 g/L
Trial: 35296402
Drug: Randomized treatment
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized treatment (Alirocumab vs Placebo)
Trial: 36480510
Drug: Active tDCS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active tDCS (20 minutes at 2 mA) for 10 daily sessions plus 5 follow up sessions
Trial: 36480510
Drug: Sham tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham tDCS (30 seconds at 2 mA, 19 minutes at 0 mA) for 10 daily sessions plus 5 follow up sessions
Trial: 35149568
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving treatment as usual, no CIH counselling
Trial: 34034627
Drug: Random forest
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random forest algorithm for predicting problem coping experiences (PCE) effects in cognitive-behavioral therapy
Trial: 34321058
Drug: Immediate tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate tapering of opioids
Trial: 32440730
Drug: Inulin-type fructans
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inulin-type fructans (16 g)
Trial: 32440730
Drug: Placebo (maltodextrin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltodextrin, 16 g)
Trial: 34344029
Drug: Givosiran (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Givosiran (monthly subcutaneous injection)
Trial: 32711554
Drug: High-dose platinum-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose platinum-based chemotherapy
Trial: 35089960
Drug: Metformin (2g/day)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (2g/day)
Trial: 35089960
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and Placebo (PCOS mothers)
Trial: 33650197
Drug: Losartan, 25
RxNorm normalized name: Hydrochlorothiazide-Losartan, 25 mg-100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan, 25 mg, twice a day
Trial: 33650197
Drug: Amlodipine, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine, 5 mg per day
Trial: 32975161
Drug: Ureteral catheter
RxNorm normalized name: Bos taurus ureter preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ureteral catheter treatment
Trial: 35988167
Drug: CNP‐EPI (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNP‐EPI (1 mL subcutaneously injected 1 day before surgery)
Trial: 34252267
Drug: Horyzons online
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Horyzons online therapy
Trial: 32468765
Drug: Prophylactic pre-operative
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic pre-operative antibiotics
Trial: 35939865
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment (Lacticaseibacillus paracasei SD1, L. rhamnosus SD4, L. rhamnosus SD11, Limosilactobacillus fermentum SD7)
Trial: 34276009
Drug: SGLT2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitors (canagliflozin 100 mg/day or dapagliflozin 5 mg/day or empagliflozin 10 mg/day)
Trial: 32621449
Drug: Razi vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Razi vaccine
Trial: 32621449
Drug: Dn vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dn vaccine
Trial: 32621449
Drug: Vc vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vc vaccine
Trial: 32621449
Drug: Ch vaccine
RxNorm normalized name: typhoid VI polysacch vaccine 25 mcg/0.5 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ch vaccine
Trial: 35652323
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention (LI) involving cognitive behavioral therapy (CBT)
Trial: 35218191
Drug: l-methionine (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-methionine (reference diet) at 0.5, 1, 2, and 3 mg.kg-1.d-1
Trial: 33397427
Drug: High-dose heparinization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose heparinization aiming for an activated clotting time (ACT) of 140–180 s
Trial: 33397427
Drug: Low-dose heparinization
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparinization aiming for a partial thromboplastin time (PTT) of 35–40 s
Trial: 33548518
Drug: Tree SLIT-tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tree SLIT-tablet (12 SQ-Bet)
Trial: 36064525
Drug: Genetically-proxied beta-blocker
RxNorm normalized name: Agalsidase beta (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically-proxied beta-blocker (BB)
Trial: 36064525
Drug: Genetically-proxied calcium
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically-proxied calcium channel blocker (CCB)
Trial: 33370444
Drug: Embedded athletic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Embedded athletic training musculoskeletal care model (2 certified athletic trainers and a sports medicine fellowship‐trained physician)
Trial: 36404525
Drug: Futibatinib 20
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Futibatinib 20 mg
Trial: 36404525
Drug: Futibatinib 80
RxNorm normalized name: Futibatinib
DrugBank: Futibatinib (DB15149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Futibatinib 80 mg
Trial: 33565691
Drug: Liraglutide (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (1.8 mg once-daily)
Trial: 33565691
Drug: Sitagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (100 mg once-daily)
Trial: 35583344
Drug: Rifampicin (RIF)
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifampicin (RIF) added to DRV/r 800/100 mg once daily (QD) and then DRV/r 800/100 twice daily (BD) and 1,600/200 QD
Trial: 35583344
Drug: DRV/r 800/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV/r 800/100 mg once daily (QD)
Trial: 33191251
Drug: Permissive hypotension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permissive hypotension (vasopressor titration to achieve MAP 60-65 mm Hg)
Trial: 33689654
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment videogame
Trial: 32996027
Drug: Daily SMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily SMS with self-care guidelines for managing side effects
Trial: 34562610
Drug: Nivolumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (1 mg/kg, Q3W) plus ipilimumab (3 mg/kg, Q3W) followed by nivolumab monotherapy (240 mg, Q2W) for up to 12 months
Trial: 34453234
Drug: Favipiravir (1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Favipiravir (1800 mg twice a day on Day 1, followed by 800 mg twice a day for up to 13 days)
Trial: 36374742
Drug: drug-laser-photon therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug-laser-photon therapy
Trial: 36254422
Drug: Dexmedetomidine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 25 mcg
Trial: 36254422
Drug: Dexmedetomidine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 50 mcg
Trial: 36254422
Drug: Dexmedetomidine 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 75 mcg
Trial: 36254422
Drug: Dexmedetomidine 100
RxNorm normalized name: dexmedeTOMIDine 1000 MG in 250 mL Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 100 mcg
Trial: 33883768
Drug: Dexamethasone 8mg
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 8mg (2mls of 4mg/ml)
Trial: 33021328
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) administered early, <3h post-injury
Trial: 32635281
Drug: Aquatic Ai
RxNorm normalized name: Mentha aquatica leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquatic Ai Chi therapy
Trial: 32635281
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (alternating sessions of physiotherapy on dry land and aquatic Ai Chi therapy)
Trial: 32635281
Drug: Physiotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy treatment on dry land (control group)
Trial: 34352829
Drug: 12‐mL paracervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12‐mL paracervical block
Trial: 34352829
Drug: 20‐mL paracervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20‐mL paracervical block
Trial: 32693214
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of stable dose of combination inhaled corticosteroid-long-acting beta-agonist
Trial: 32693214
Drug: Step-down of
RxNorm normalized name: Kool-Down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step-down of inhaled corticosteroid
Trial: 32693214
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of long-acting bronchodilator
Trial: 32144908
Drug: Herbal cake-partitioned
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal cake-partitioned moxibustion combined with Rhinocort spray (256 µg/d, once in the morning and evening, for 4 weeks)
Trial: 32144908
Drug: Rhinocort spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhinocort spray alone (256 µg/d, once in the morning and evening, for 4 weeks)
Trial: 32593524
Drug: Ursolic acid
RxNorm normalized name: Ursolic Acid
DrugBank: Ursolic acid (DB15588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursolic acid (UA) 400 mg/d
Trial: 32593524
Drug: Placebo 400
RxNorm normalized name: placebo 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 400 mg/d
Trial: 36089810
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg + Losartan 50 mg
Trial: 33971067
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy (major autohemotherapy) applied to 37 patients, consisting of seven sessions of intravenous ozone administration (100 mL, 30 μg/mL)
Trial: 33971067
Drug: Conventional COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional COVID-19 treatment applied to 18 patients in the control group
Trial: 35169095
Drug: Bevacizumab, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor.
Trial: 33188747
Drug: Nitazoxanide (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitazoxanide (1.0 g/day) for 14 days
Trial: 33188747
Drug: Mesalazine (1.5-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine (1.5-2 g/day) for 14 days
Trial: 33188747
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nitazoxanide (1.0 g/day) and mesalazine (≥1.5-2 g/day) for 14 days
Trial: 33866933
Drug: Daily intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intake of 100 mg oral ferrous fumarate
Trial: 33866933
Drug: Every other
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every other day intake of 100 mg oral ferrous fumarate
Trial: 33006615
Drug: Cold Atmospheric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold Atmospheric Plasma Therapy
Trial: 33006615
Drug: Standard Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Therapy Placebo
Trial: 35258042
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplements (ONS) twice per day for 7 days before surgery
Trial: 33955943
Drug: Deep sclerectomy
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep sclerectomy with intrascleral collagen implant (DSCI)
Trial: 33955943
Drug: Deep sclerectomy
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep sclerectomy with suprachoroidal collagen implant (DSSCI)
Trial: 34707516
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (including but not limited to antidepressant medication and/or psychotherapy)
Trial: 33010094
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no homeopathic treatment)
Trial: 35577034
Drug: Lisdexamfetamine (LDX)
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine (LDX) 10, 20, 30 mg pooled
Trial: 33846555
Drug: Colostrum (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colostrum (200 mg/L)
Trial: 33846555
Drug: Transitional milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transitional milk (171 mg/L)
Trial: 33846555
Drug: Mature milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mature milk (126 mg/L)
Trial: 33992249
Drug: Pilates training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilates training (2 to 4 weekly sessions for 10 weeks)
Trial: 32964939
Drug: Fresh embryo
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh embryo transfer with intensified luteal phase support (1500 IU hCG, oral estradiol 2 mg twice daily, micronized vaginal progesterone 200 mg three times daily)
Trial: 34268513
Drug: Therapeutic heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic heparin
Trial: 35099997
Drug: Prophylactic-dose heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic-dose heparin
Trial: 39709402
Drug: L-PRF alone
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-PRF alone
Trial: 32416830
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet supplemented with 10 mg Zn/kg feed
Trial: 32416830
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet supplemented with 20 mg Zn/kg feed
Trial: 32416830
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet supplemented with 40 mg Zn/kg feed
Trial: 32416830
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet supplemented with 80 mg Zn/kg feed
Trial: 32416830
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet supplemented with 160 mg Zn/kg feed
Trial: 32416830
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet (27.7 mg/kg Zn)
Trial: 35848821
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (1 ml triamcinolone 40 mg/ml under ultrasound guidance)
Trial: 33783516
Drug: Shortened duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shortened duration of adjuvant chemotherapy (3 to 5 months) with CAPOX (capecitabine plus oxaliplatin)